TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05383794

Intervention type: OTHER
Intervention: Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Description: Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.

Intervention type: OTHER
Intervention: Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Description: Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Study: NCT03946891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Furosemide
Description: Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Furosemide
Description: Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
Study: NCT03621163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bleaching agent ( BOOST 40%)
Description: Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminate veneers(lithium-silicate)
Description: A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
Study: NCT03388853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine/Doxofylline
Description: Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for four weeks.
Study: NCT03055637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Furlow double opposing z-plasty
Description: \* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Furlow double opposing z-plasty
Description: \* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two flap palatoplasty
Description: design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two flap palatoplasty
Description: design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
Study: NCT00886470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
Study: NCT00912821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 L dialysate
Description: 6 L peritoneal dialysis solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8 L dialysate
Description: 8 L peritoneal dialysis solution
Study: NCT01929330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.1 mg
Description: It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.1 mg
Description: It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.5 mg
Description: It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI198745 0.5 mg
Description: It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
Study: NCT02693912

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Bronchoscopy will be implemented under sedation in both groups.
Study: NCT03086343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Film-coated tablet
Study: NCT02296697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy AlGaInP
Description: Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency therapy with O3 formation
Description: High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
Study: NCT03748979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925
Study: NCT02296697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing with saline solution
Description: Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing with saline solution
Description: Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wound dressing with saline solution
Description: Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
Study: NCT02263313

Intervention type: OTHER
Intervention: EGO-COMBO group
Description: Assess the safety and effectiveness of Combo stent
Study: NCT04689243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Description: Low concentration ALA-PDT, 3 times a week.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: red light
Description: red light, 3 times a week.
Study: NCT01801332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intensive nutrition
Description: Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: usual meals
Description: Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily.
Study: NCT01149967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram Hydrobromide
Description: Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
Study: NCT00447278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other standard therapy for ADHD
Description: Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
Study: NCT00167271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
Study: NCT01039675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mcg/25mcg once daily
Description: GSK573719/GW642444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once daily
Description: Inactive, excipients only
Study: NCT01186081

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Description: Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemoradiotherapy
Description: Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
Study: NCT03339362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Procedure
Description: If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint.
Study: NCT01359423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Study: NCT02450136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Study: NCT00219271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT04697901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes.
Study: NCT03748979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-925 Placebo
Study: NCT02698280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimustine
Description: Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
Study: NCT02260089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02392767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Verum
Description: 2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn starch
Study: NCT01629654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion program
Description: A 13 weeks organized program:~* One group session about poststroke fatigue involving both patient and relatives~* Two personal meetings, involving both patient and relatives~* Three telephone meetings, involving only patient
Study: NCT00627042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B)
Description: Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
Study: NCT03376555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine (ACh) Dose Response
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) Dose Response
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) Dose Response
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) Dose Response
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) Dose Response
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Heating (LH)
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin